Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension
Lead Sponsor:
Pfizer
Conditions:
Hypertension
Eligibility:
All Genders
19-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the response rate for the therapeutic goal (diastolic blood pressure (BP) less than 90 mmHg and systolic BP less than 140 mmHg) at Week 6 for quinapril 20 mg ...
Eligibility Criteria
Inclusion
- A clinical diagnosis of mild to moderate primary hypertension ("Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 6th report" Stage I or II)
- Sitting diastolic blood pressure between 90 mmHg and 109 mmHg and systolic blood pressure between 140 mmHg and 179 mmHg at the end of the no-treatment run-in period
Exclusion
- Subjects with secondary hypertension
- Subjects with serious cardiac disease (including myocardial infarction in the last 3 months or decompensated heart failure)
- Subjects who do not accept to stop using any other antihypertensive treatment during the run-in period and the treatment period of the study
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00651287
Start Date
December 1 2002
End Date
June 1 2004
Last Update
April 10 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Cerrahpaşa, Istanbul, Turkey (Türkiye), 34300
2
Pfizer Investigational Site
Diyarbak R, Turkey (Türkiye), 21280
3
Pfizer Investigational Site